Secondary analysis of MA.32 (2740 with blood samples): baseline CA 15-3 was not associated with distant recurrence-free survival in any subtype; a rise at 6 months was, in luminal (HR 1.41 per 25%) and triple-negative (HR 1.35) disease but not HER2-positive.
Secondary analysisn = 2,740
Goodwin et al. Association of cancer antigen 15-3 with distant recurrence in immunohistochemically defined breast cancer subtypes in Canadian Cancer Trials Group MA.32